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Between September 2017 and February 2018, influ-
enza A(H1N1)pdm09, A(H3N2) and B viruses (mainly 
B/Yamagata, not included in 2017/18 trivalent vac-
cines) co-circulated in Europe. Interim results from 
five European studies indicate that, in all age groups, 
2017/18 influenza vaccine effectiveness was 25 to 52% 
against any influenza, 55 to 68% against influenza 
A(H1N1)pdm09, −42 to 7% against influenza A(H3N2) 
and 36 to 54% against influenza B. 2017/18 influenza 
vaccine should be promoted where influenza still 
circulates.
Most countries in the European Union (EU) recommend 
and fund seasonal influenza vaccine for elderly people 
and individuals at increased risk of severe influenza [1]. 
The United Kingdom (UK) commenced the incremental 
introduction of a universal childhood influenza vacci-
nation programme in 2013/14 using a quadrivalent live 
attenuated influenza vaccine (LAIV4) for healthy chil-
dren and quadrivalent inactivated vaccine (QIV) for at-
risk children for whom LAIV4 is contraindicated [2].
The trivalent influenza vaccines for the 2017/18 
northern hemisphere influenza season include an 
A/Michigan/45/2015 (H1N1)pdm09-like virus, an 
A/Hong Kong/4801/2014 (H3N2)-like virus and a 
B/Brisbane/60/2008-like virus (B/Victoria line-
age). The quadrivalent vaccines also contain a B/
Phuket/3073/2013-like virus (B/Yamagata lineage) [3].
The early phase of the 2017/18 influenza season in 
Europe was characterised by the co-circulation of influ-
enza A(H1N1)pdm09, influenza A(H3N2) and influenza 
B, with different patterns of dominant type or subtype 
observed between countries [4]. Up to February 2018, 
most influenza B viruses assigned to a lineage were B/
Yamagata viruses, not included in the 2017/18 trivalent 
vaccine [3,4].
Here we present the interim 2017/18 season influenza 
vaccine effectiveness (VE) estimates from three single-
country studies (UK, Denmark (DK) and Spain (ES)) 
and two multi-country studies (primary care (EU-PC) 
and hospital (EU-H) European Influenza - Monitoring 
Vaccine Effectiveness (I-MOVE/I-MOVE+) networks) 
(Figure 1). 
Study design and estimation of vaccine 
effectiveness 
The methods of these five studies have been described 
in detail elsewhere [5-9]. Study sites included in 
EU-PC (Croatia, France, Germany, Ireland, Italy, the 
Netherlands, Portugal, Spain and Sweden) and EU-H 
(France, Italy, the Netherlands, Portugal and Spain) 
followed generic protocols for primary care-based or 
hospital-based studies.
All five studies used a test-negative case control design 
(TND) [10]. In short, individuals presenting at partici-
pating healthcare settings with a pre-determined set 
of symptoms (including at least one systemic and one 
respiratory symptom) were swabbed. Samples were 
tested for influenza using RT-PCR. Individuals testing 
positive for influenza were classified as cases (by influ-
enza (sub)type), those testing negative as controls.
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The ES, UK and EU-PC studies included patients at pri-
mary care level (henceforth referred to as medically 
attended), the EU-H study included patients at hospital 
level (henceforth referred to as hospitalised), and the 
DK study included results from primary care and hospi-
tal level pooled together. Patients’ inclusion was fore-
seen to be systematic (or exhaustive) in the ES, EU-PC 
and EU-H studies and ad hoc in the DK and UK studies. 
In Spain, 268 of the 833 physicians included in the ES 
study were also included in the EU-PC study.
The study population included all age groups in all 
studies except for EU-H, which was confined to indi-
viduals 65 years and older.
In all studies, we defined patients as vaccinated with 
the 2017/18 influenza vaccine if they had been vacci-
nated at least 14 days (UK) or 15 days (all other studies) 
before symptom onset. Patients were excluded if they 
were vaccinated less than 14 (UK) or 15 days (all other 
studies) before symptom onset or if the date of vacci-
nation was unknown.
Figure 1
European Union countries contributing to the influenza vaccine effectiveness results presented, by study, 2017/18 
(n = 21,220)
Not included
EU-PC
EU-PC and EU-H
EU-PC, EU-H and ES
DK
UK
DK: Denmark study; ES: Spain study; EU-H: European hospital-based multi-country I-MOVE+ study; EU-PC: European primary care-based 
multi-country I-MOVE/I-MOVE+ study; UK: United Kingdom study.
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In seven EU-PC countries (France, Germany, Ireland, 
the Netherlands, Portugal, Spain and Sweden), the UK, 
ES and DK, all or a random sample of positive influenza 
specimens were selected for genetic sequencing.
VE was computed by comparing the odds of vaccina-
tion between cases and controls (VE = (1 − OR) × 100). 
All studies used logistic regression to adjust VE for 
measured confounding variables, excluding patients 
with missing data for covariates in the model (complete 
case analysis) (Table 1). We computed VE overall and, 
where possible, by age group and target population 
(as defined locally in the various studies and study 
sites) against any influenza, influenza A(H3N2), influ-
enza A(H1N1)pdm09, any influenza B and influenza B/
Yamagata.
If the number of events per parameter was lower than 
10, we conducted a sensitivity analysis using penalised 
logistic regression to assess small sample bias [11].
Results 
Between September 2017 and February 2018, the num-
ber of patients included in the VE analysis by study 
was 2,399 (1,452 cases) in the ES, 1,331 (421 cases) 
in the UK, 4,652 (2,103 cases) in the EU-PC, 11,907 
(3,011 cases) in the DK and 931 (385 cases) in the EU-H 
study. Overall, more than two thirds of cases were 
positive for influenza B viruses in all studies except 
UK, where influenza A and B viruses were detected in 
similar proportions (51% (214/423) and 49% (209/423), 
respectively) (Figure 2). Where subtyped, influenza A 
viruses were mainly A(H3N2) in ES (62% (233/375) of 
subtyped influenza A specimens), UK (90% (174/194)) 
and EU-H (74% (68/92)), and mainly A(H1N1)pdm09 in 
DK (56% (145/257)) and EU-PC (67% (469/698)). 
Any influenza
Among all ages, VE against any medically attended 
influenza ranged between 25% (95% confidence inter-
val (CI): −10 to 48) in the UK study and 52% (95% CI: 
29 to 67) in the ES study. In UK, VE of the LAIV4 was 
53% (95% CI: −56 to 86) in children and VE of the inac-
tivated vaccine was 18% (95% CI: −23 to 45) in adults 
(Table 2). Among the target groups for influenza vac-
cination, the VE was 36% (95% CI: 13 to 53) in EU-PC 
and 40% (95% CI: 1 to 63) in the ES study. In EU-H, VE 
against any hospitalised influenza in patients aged 65 
years and older was 35% (95% CI: 13 to 51).
Influenza A(H1N1)pdm09
All 76 influenza A(H1N1)pdm09 viruses sequenced 
belonged to clade 6B.1 (A/Michigan/45/2015) (Table 2).
VE against influenza A(H1N1)pdm09 was 68% (95% CI: 
42 to 83) and 55% (95% CI: 23 to 74) among all ages in 
the EU-PC and DK studies, respectively. Among 18–64 
year-olds, it was 63% (95% CI: 12 to 84) and 60% (95% 
CI: 13 to 82) in the EU-PC and DK studies, respectively. 
Among those aged 65 years and older, it was 37% (95% 
CI: −40 to 72) in the DK study (Table 2).
Influenza A(H3N2)
Of the 204 influenza A(H3N2) viruses sequenced, 63% 
(n = 129) belonged to genetic clade 3C.2a, 35% (n = 72) 
to 3C.2a1 and 1% (n = 3) to 3C.3a (Table 3).
Among all ages, VE against influenza A(H3N2) ranged 
from −42% (95% CI: −116 to 7) in the DK and 7% (95% 
CI: −74 to 51) in the ES study. VE against hospitalisation 
for influenza A(H3N2) in patients aged 65 years and 
older was −1% (95% CI: −93 to 47) in EU-H (Table 2).
Influenza B
Of the 596 influenza B viruses sequenced, 94% 
(n = 559) were B/Yamagata (all belonging to clade 3 
influenza B/Phuket/3073/2013) and 6% (n = 37) were 
influenza B/Victoria (25 belonging to clade 1A Δ(K162, 
N163) and 12 belonging to clade 1A) (Table 3).
Among all ages, VE against influenza B ranged between 
36% (95% CI: 27 to 44) in the DK and 54% (95% CI: 
24 to 72) in the UK study. Age group-specific VE was 
lowest at 15% (95% CI: −114 to 66) among those aged 
65 years and older and highest at 83% (95%CI: 54 to 
94) in the 0–14-year age group in the ES study. VE was 
34% (95% CI: 8 to 52) against hospitalised influenza 
B in EU-H and 28% (95% CI: 14 to 39) against medi-
cally attended and hospitalised influenza B in the DK 
study among those aged 65 years and older (Table 2). 
VE against influenza B/Yamagata was 77% (95% CI: 14 
to 94) in the ES study and 49% (95% CI: 19 to 67) in 
EU-PC (Table 2).
Figure 2
Proportion of influenza (sub)types by study, Europe, 
2017/18 (n = 6,979)
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DK: Denmark study; ES: Spain study; UK: United Kingdom study; 
EU-H: European hospital-based multi-country I-MOVE+ study; 
EU-PC: European primary care-based multi-country I-MOVE/I-
MOVE+ study.
a Includes two influenza A(H1N1)pdm09/B co-infections; 98 of 
influenza A(H1N1)pdm09, 122 of A(H3N2) and 454 of B cases 
were also in ES.
The graph includes individuals excluded from the VE analysis due 
to missing covariates.
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Sensitivity analyses
For all of the above analyses, sensitivity analyses for 
small sample size gave similar results (absolute differ-
ence ranging between 1% and 6%).
 
Discussion 
Interim results from five established influenza VE stud-
ies across Europe indicate that 2017/18 VE against 
all influenza ranged between 25 and 52% among all 
ages and between 36 and 40% in the targeted groups. 
VE was moderate to good against influenza A(H1N1)
pdm09 among all ages (55 to 68%), poor against influ-
enza A(H3N2) with all point estimates below 8% for 
all ages, and moderate against influenza B, with point 
estimates between 39 and 52% for all ages.
The good VE against medically attended influenza 
A(H1N1)pdm09 is consistent with historical data [12]. 
However, during the last influenza A(H1N1)pdm09 sea-
son in Europe (2015/16), the EU-PC VE of 33% against 
influenza A(H1N1)pdm09 in all age groups was lower 
than what we report here [13]. In the 2015/16 season, 
the influenza vaccine strain A/California/7/2009 (H1N1)
pdm09 differed from the circulating strains which 
mainly belonged to the genetic subgroup 6B.1 (rep-
resented by A/Michigan/45/2015 (H1N1)pdm09). This 
6B.1 strain was included in the 2017/18 vaccine and was 
identified in all A(H1N1)pdm09 samples sequenced in 
the study sites. The change in vaccine strain may have 
led to a better VE against A(H1N1)pdm09. More precise 
end-of-season estimates and results at the hospital 
level will help investigate this hypothesis.
The influenza A(H3N2) component included in the 
2017/18 northern hemisphere vaccine was the same 
as in the 2016/17 northern hemisphere vaccine [14]. 
As anticipated based on EU-H 2016/17 results [15] and 
Table 1
Summary characteristics of the influenza vaccine effectiveness studies included, Europe, influenza season 2017/18 
(n = 21,220)
 ES  UK EU-PC DK EU-H
Study period 30 Oct 2017 to 21 Jan 2018
1 Oct 2017 to 14 Jan 
2018
25 Sep 2017 to 26 Jan 
2018 1 Dec 2017 to 5 Feb 2018 25 Oct 2017 to 4 Feb 2018
Setting Primary care Primary care Primary care Primary care and hospital Hospital
Location Spain
England, Scotland, 
Northern Ireland and 
Wales
Croatia, France, Germany, 
Ireland, Italy, the 
Netherlands, Portugal, 
Spain and Sweden
Denmark
France, Italy, the 
Netherlands, Portugal and 
Spain
Study design TND TND TND TND TND
Data source
Sentinel 
physicians and 
laboratory
Sentinel physicians 
and laboratory
Sentinel physicians and 
laboratorya
Data linkage of Danish 
Microbiology Database, 
the Danish Vaccination 
Register and the Danish 
National Hospital Register
Hospital charts, vaccine 
registers, interviews 
with GPs/pharmacists, 
laboratory
Age group 
of study 
population
All All ≥ 6 months ≥ 18 years ≥ 65 years
Case 
definition ILI ILI ILI ILI SARI
Selection of 
patients Systematic
At practitioner‘s 
discretion Systematic
At practitioner‘s 
discretion Exhaustive
Vaccine types 
usedb
Mostly TIV (no 
individual data)
In children: 19% TIV, 
77% LAIV4 nasal 
spray, 3% unknown 
 
In adults: 100% 
unknown
67% TIV, 17% unknown, 
8% TIV adjuvanted, 4% 
QIV, 3% TIV intradermal, 
1% LAIV4 nasal spray
Only TIV (no individual 
data)
57% TIV, 25% unknown, 
8% TIV adjuvanted, 10% 
TIV intradermal
Variables of 
adjustment
Age (RCS), 
sex, presence 
of chronic 
conditions, 
onset date, 
region
Age group, sex, onset 
date, pilot area for 
child vaccination 
programme, 
surveillance scheme
Age (RCS), sex, presence 
of chronic conditions, 
onset date and study site
Age group, sex, presence 
of chronic conditions, 
onset date
Age (RCS), lung diseases, 
heart diseases, diabetes 
mellitus, obesity 
(BMI ≥ 30), renal diseases, 
cancer and hospitalisation 
in the past 12 months, 
onset date, study site
DK: Denmark study; ES: Spain study; EU-H: European hospital-based multi-country I-MOVE+ study; EU-PC: European primary care-based 
multi-country I-MOVE/I-MOVE+ study; GP: general practitioner; ILI: influenza-like illness; LAIV4: quadrivalent live attenuated influenza 
vaccines; LRI: lower respiratory infection; SARI: severe acute respiratory infection; TIV: trivalent inactivated vaccines; TND: test-negative 
design; RCS: restricted cubic spline; UK: United Kingdom study.
a In Spain, 268 of the 833 physicians included in the ES study were also included in the EU-PC study.
b Vaccines were egg-propagated, non-adjuvanted and administered intramuscularly unless otherwise specified.
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Table 2
Interim adjusted seasonal vaccine effectiveness against any laboratory-confirmed influenza, influenza A(H1N1)pdm09, 
A(H3N2) and B, by age group, target group for vaccination and by study, Europe, influenza season 2017/18
Influenza type/subtype and 
study site
Setting Study population
Cases Controls
Adjusted VE 95% CI
All Vacc % All Vacc %
Influenza A + B
ES  PC
All ages 1,452 98 7 947 75 8 52 29 to 67
0–14 years 589 15 3 370 13 4 78 45 to 91
15–64 years 762 44 6 511 40 8 54 23 to 73
≥ 65 years 101 42 42 66 22 33 21 −93 to 68
Target groupa 278 72 26 180 50 28 40 1 to 63
UK PC
All ages 421 93 22 910 190 21 25 −10 to 48
2–17 years (LAIV4) 69 5 7 166 19 11 53 −56 to 86
≥ 18 years (IIV) 347 87 25 630 163 26 18 −23 to 45
EU-PC PC
All ages 2,103 210 10 2,549 272 11 38 20 to 52
0–17 years 846 26 3 998 35 4 59 23 to 78
18–64 years 1,021 74 7 1,288 109 8 34 5 to 54
≥ 65 years 234 110 47 262 128 49 44 8 to 66
Target groupa 554 172 31 713 217 30 36 13 to 53
DK PC and hospital
All ages 3,011 593 20 8,896 2299 26 34 25 to 41
18–64 years 1,564 136 9 3,462 538 16 47 35 to 58
≥ 65 years 934 447 48 3,089 1,688 55 23 10 to 34
EU-H Hospital ≥ 65 years 385 200 52 546 332 61 35 13 to 51
Influenza A(H1N1)pdm09
EU-PC PC
All ages 444 14 3 1,999 195 10 68 42 to 83
18–64 years 203 7 3 955 77 8 63 12 to 84
DK PC and hospital
All ages 214 18 8 8,896 2299 26 55 23 to 74
18–64 years 119 7 6 3,462 538 16 60 13 to 82
≥ 65 years 26 11 42 3,089 1,688 55 37 −40 to 72
Influenza A(H3N2)
ES  PC All ages 233 22 9 947 75 8 7 −74 to 51
UK PC All ages 194 58 30 910 190 21 −27 −111 to 24
EU-PC PC
All ages 220 35 16 1,505 147 10 −16 −96 to 31
18–64 years 140 9 6 771 66 9 27 −62 to 67
DK PC and hospital
All ages 122 53 43 8,896 2,299 26 -42 −116 to 7
18–64 years 45 6 13 3,462 538 16 21 −95 to 68
≥ 65 years 67 45 67 3,089 1,688 55 −65 −178 to 2
EU-H Hospital ≥ 65 years 60 38 63 242 154 64 −1 −93 to 47
Any influenza B
ES  PC
All ages 1,022 72 7 947 75 8 52 27 to 68
0–17 years 440 10 2 370 13 4 83 54 to 94
18–64 years 503 31 6 511 40 8 51 13 to 72
≥ 65 years 79 31 39 66 22 33 15 −114 to 66
Target groupa 207 53 26 180 50 28 38 −5 to 63
UK PC All ages 209 33 16 910 190 21 54 24 to 72
EU-PC PC
All ages 1,368 150 11 2,510 269 11 39 19 to 54
0–17 years 562 21 4 980 35 4 58 15 to 79
18–64 years 643 55 9 1,279 108 8 27 −9 to 51
≥ 65 years 161 74 46 250 126 50 54 20 to 73
Target groupa 382 125 33 696 215 31 39 14 to 56
DK PC and hospital
All ages 2,298 437 19 8,896 2,299 26 36 27 to 44
18–64 years 1,220 111 9 3,462 538 16 44 30 to 56
≥ 65 years 701 319 46 3,089 1,688 55 28 14 to 39
EU-H Hospital ≥ 65 years 249 131 53 524 321 61 34 8 to 52
Influenza B/Yamagata
ES  PC All ages 84 4 5 993 81 8 77 14 to 94
EU-PCb PC All ages 395 34 9 2,065 206 10 49 19 to 67
CI: confidence interval; DK: Denmark study; ES: Spain study; EU-H: European hospital-based multi-country I-MOVE+ study; EU-PC: European primary care-based multi-
country I-MOVE/I-MOVE+ study; PC: primary care; UK: United Kingdom study; Vacc: vaccinated; VE: vaccine effectiveness.
a Groups targeted by seasonal influenza vaccination as defined locally in the studies and study sites.
b Only includes study sites where lineage was available for all samples or where lineage was determined systematically.
Study sites included in the EU-H analysis: France, Italy, Navarra, the Netherlands, Portugal and Spain (except for influenza A(H3N2) analysis: Navarra and Spain only).
Study sites included in EU-PC analysis for all influenza and influenza B: Croatia, France, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden. For analysis 
against A(H1N1)pdm09: France, Germany, Italy and Spain were included. For analysis against A(H3N2): France, Germany, Ireland, Spain and Sweden were included.
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2017 interim results from Australia [16], and as already 
reported in other published early estimates for the 
northern hemisphere [17], the VE against influenza 
A(H3N2) was low in participating study sites. In our 
studies, 63% of sequenced influenza A(H3N2) viruses 
belonged to the A/HongKong/4801/2014 vaccine strain 
genetic group (3C.2a) and 35% to the A/Singapore/
INFIMH-16–0019/2016 clade (3C.2a1), which is the 
selected strain in the 2018 southern hemisphere and 
2018/19 northern hemisphere influenza vaccines [18]. 
Small sample size limited VE estimation by clade and 
subclade, which will be a priority for end-of-season 
analyses. Our results further support the need for 
more effective interventions in older people, in whom 
the burden of influenza A(H3N2) is most notable and 
the VE, including against severe outcome, is the lowest 
[19]. Based upon recent cost-effectiveness work under-
taken by Public Health England, the UK Joint Committee 
on Vaccination and Immunisation has advised that 
use of adjuvanted trivalent inactivated vaccines (TIV) 
in those aged 65 years and older would be both more 
effective and cost-effective than the non-adjuvanted 
trivalent or quadrivalent vaccines currently in use [20].
The interim VE against medically attended influenza B 
was moderate in the studies included here (36% to 54% 
among all ages), similar to recently published estimates 
from northern hemisphere countries [17,21,22]. It was 
moderate to good against medically attended influenza 
B in children (58% in EU PC and 83% in ES) and poorer 
at 34% against hospitalised outcome among adults 65 
years and older. The vast majority (94%) of sequenced 
influenza B samples were of the B/Yamagata lineage, 
which was not included in the 2017/18 northern hemi-
sphere TIV. VE was 77% and 49% against influenza B/
Yamagata in the ES and EU-PC studies, respectively, 
suggesting important cross-lineage protection.
The UK study was the only one to provide VE estimates 
for the quadrivalent vaccines. Vaccine effectiveness 
against any influenza among children was similar in the 
UK study (53%), where children receive LAIV4, and in 
the EU-PC study (59%), where most vaccinated children 
received TIV. However, it is difficult to compare these 
estimates against any influenza since the relative pro-
portion of circulating (sub)types was different in the 
UK, where there was a higher proportion of circulating 
influenza A(H3N2) viruses, compared with most coun-
tries participating in the EU-PC study. In past seasons 
where circulating and vaccine lineages were different, 
contradictory results were observed [13,23,24]. Partial, 
but not full cross-protection between mismatched influ-
enza B lineages has been suggested by two systematic 
reviews [25,26]. More precise end-of-season estimates 
by lineage, age group and vaccine type would be of 
added value to discuss cross-lineage protection and 
the added protection conferred by quadrivalent vac-
cines. Such information is relevant at a time when QIV 
is available in most European countries [27] and prefer-
entially recommended in some [28].
End-of-season analyses are needed to verify the con-
clusions from these interim season results. A larger 
sample size should allow more precise estimates, 
Table 3
Influenza viruses characterised by clade and study site, Europe, influenza season 2017/18 (n = 886)
Clade
 ES a UK EU-PCb DKc
n % n % n % n %
Total influenza A(H1N1) n = 142 n = 20 n = 469 n = 113
Sequenced 28 100 10 100 25 100 23 100
A/Michigan/45/2015 6B.1 28 100 10 100 25 100 23 100
Total influenza A(H3N2) n = 233 n = 174 n = 229 n = 144
Sequenced 51 100 59 100 43 100 51 100
A/HongKong/4801/2014 3C.2a 20 39 46 78 27 63 36 71
A/Singapore/INFIMH-16–0019/2016 3C.2a1 31 61 10 17 16 37 15 29
A/Switzerland/9715293/2013 3C.3a 0 0 3 5 0 0 0 0
Total influenza B n = 1,022 n = 209 n = 1,469 n = 625
Sequenced 164 100 116 100 207 100 109 100
B/Yamagata 136 83 116 100 198 96 109 100
B/Phuket/3073/2013 3 136 100 0 0 198 100 109 100
B/Victoria 28 17 0 0 9 4 0 0
B/Norway/2409/2017 1A Δ(K162, N163) 20 71 0 0 5 56 0 0
B/Brisbane/60/2008 1A 8 29 0 0 4 44 0 0
a 50 specimens from ES are also included in EU-PC data.
b The specimens sequenced from Spain are originating from the entire National Influenza Surveillance System between weeks 44/2017 and 
03/2018.
c Sequence information is based on a sub-sample of influenza-positive samples received for surveillance at the National Influenza Center 
Denmark from week 40/2017 to 4/2018.
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especially in stratified analyses. Recent publica-
tions suggest a potentially strong (boosting or lower-
ing) effect of previous vaccination on VE estimates 
[29,30] and end-of-season analyses should take this 
into account. Although TND is a well-recognised study 
design to measure VE, we cannot rule out bias from 
unmeasured confounding.
These early VE results from five studies were included 
in the Global Influenza VE (GIVE) report to help inform 
the World Health Organization vaccine strain selec-
tion committee meeting on 22 February 2018. For the 
2018/19 northern hemisphere trivalent vaccine, this 
selection committee recommended to include the 
same influenza A(H1N1) component as in the 2017/18 
northern hemisphere vaccine, an A/Singapore/
INFIMH-16–0019/2016 (H3N2)-like virus and a B/
Colorado/06/2017-like virus (B/Victoria/2/87 lineage) 
[18].
In the context of an influenza season with co-circula-
tion of influenza A(H3N2), influenza A(H1N1)pdm09 and 
influenza B viruses mismatched with the trivalent vac-
cine, results from these five EU studies indicate a mod-
erate VE against all influenza. Vaccination continues 
to be the most effective preventive measure against 
influenza and uptake of the 2017/18 trivalent or quad-
rivalent influenza vaccines should still be promoted in 
countries with ongoing virus circulation. In particular in 
settings with evidence of influenza A(H3N2) virus circu-
lation, prophylactic use of antiviral drugs, administered 
according to country-specific guidelines, could help 
prevent severe outcomes [31]. Based on our results and 
in the absence of major antigenic drift, we may expect 
a good protection of the 2018/19 northern hemisphere 
seasonal influenza vaccine against influenza A(H1N1) 
and B viruses. Monitoring the effectiveness of the 2018 
southern influenza vaccine against influenza A(H3N2) 
viruses will be important to prepare for the next influ-
enza season in the northern hemisphere.
I-MOVE/I-MOVE+ group
Croatia
EU-PC study:
Bernard Kaic, Croatian Institute of Public Health, Zagreb
Sanja Kurecic Filipovic, Croatian Institute of Public Health, 
Zagreb
Vesna Visekruna-Vucina, Croatian Institute of Public Health, 
Zagreb
Iva Pem Novosel, Croatian Institute of Public Health, Zagreb
Zvjezdana Lovric, Croatian Institute of Public Health, Zagreb
Goranka Petrović, Croatian Institute of Public Health, Zagreb
Denmark
DK study:
Tyra Grove Krause, Department of Infectious Disease 
Epidemiology and Prevention, Statens Serum Institut, 
Artillerivej 5, 2300 Copenhagen S, Denmark
Thea Kølsen Fische, Department of Virus and Microbiological 
Special diagnostics, National Influenza Center, Statens 
Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
France
EU-PC and EU-H studies:
Bruno Lina, Laboratoire de Virologie, CNR des virus des 
infections respiratoires, Institut des Agents Infectieux, 
Groupement Hospitalier Nord des HCL, Lyon, France; 
Laboratoire Virpath, CIRI Inserm U1111, CNRS 5308, ENS, 
UCBL, Faculté de Médecine LYON Est, Université de Lyon, 
Lyon.
EU-PC study:
Alessandra Falchi, EA7310, Laboratoire de Virologie, 
Université de Corse-Inserm, FR- 20250, Corte, France
Ana-Maria Vilcu, Cécile Souty, Thierry Blanchon, Sorbonne 
Université, INSERM, Institut Pierre Louis d’Epidémiologie et 
de Santé Publique (IPLESP), F75012 Paris.
Sylvie van der Werf, Unité de Génétique Moléculaire des 
Virus à ARN, UMR 3569 CNRS, Université Paris Diderot SPC, 
Institut Pasteur, Paris; CNR des virus des infections respira-
toires, Institut Pasteur, Paris
Vincent Enouf, Unité de Génétique Moléculaire des Virus à 
ARN, UMR 3569 CNRS, Université Paris Diderot SPC, Institut 
Pasteur, Paris ; CNR des virus des infections respiratoires, 
Institut Pasteur, Paris.
Sylvie Behillil, Unité de Génétique Moléculaire des Virus à 
ARN, UMR 3569 CNRS, Université Paris Diderot SPC, Institut 
Pasteur, Paris; CNR des virus des infections respiratoires, 
Institut Pasteur, Paris.
Martine Valette, Laboratoire de Virologie, CNR des virus 
des infections respiratoires, Institut des Agents Infectieux, 
Groupement Hospitalier Nord des HCL, Lyon.
Sibylle Bernard-Stoecklin, Santé publique France, Paris.
Daniel Lévy-Bruhl, Santé publique France, Paris.
EU-H study:
Odile Launay, Innovative clinical research network in vacci-
nology, I-REIVAC, CIC Cochin-Pasteur, Paris
Pierre Loulergue, I-REIVAC, CIC Cochin-Pasteur, Paris
Nezha Lenzi, I-REIVAC, Paris
Zineb Lesieur, I-REIVAC, Paris
Anne-Sophie L’Honneur, service de Virologie, Hôpital Cochin, 
Paris
Florence Galtier: CIC 1411, hôpital St Eloi, CHU de Montpellier 
; Inserm, F-CRIN, I-REIVAC
Camille Agostini, CIC 1411, hôpital St Eloi, CHU de Montpellier
Chris Serrand, CIC 1411, hôpital St Eloi, CHU de Montpellier
Corinne Merle, Service des Maladies Infectieuses et 
Tropicales, Hôpital Gui de Chauliac, CHU de Montpellier
Vincent Foulongne, Pathogenesis and Control of Chronic 
Infections, Univ. Montpellier, INSERM, EFS, CHU Montpellier, 
Montpellier, France
Philippe Vanhems, I-REIVAC; Hôpital Edouard Herriot, Lyon
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Fabrice Lainé, I-REIVAC; CIC 1414, Hôpital Pontchaillou, 
Rennes
Gisèle Lagathu, laboratoire de virologie, C.H.U de Rennes
Fabrice Carrat, UPMC Univ Paris 06, IPLESP UMRS 1136, 
Public health department, Hôpital Saint-Antoine, Paris
Germany
EU-PC study:
Silke Buda, Department for Infectious Disease Epidemiology, 
Robert Koch Institute, Berlin
Ute Preuss, Department for Infectious Disease Epidemiology, 
Robert Koch Institute, Berlin
Kerstin Prahm, Department for Infectious Disease 
Epidemiology, Robert Koch Institute, Berlin
Brunhilde Schweiger, National Reference Center for 
Influenza, Robert Koch Institute, Berlin
Marianne Wedde, National Reference Center for Influenza, 
Robert Koch Institute, Berlin
Alla Heider, National Reference Center for Influenza, Robert 
Koch Institute, Berlin
Maria Martin, National Reference Center for Influenza, Robert 
Koch Institute, Berlin
Barbara Biere, National Reference Center for Influenza, 
Robert Koch Institute, Berlin
Ralf Duerrwald, National Reference Center for Influenza, 
Robert Koch Institute, Berlin
Ireland
EU-PC study:
Lisa Domegan, HSE-Health Protection Surveillance Centre, 
Dublin
Laura Coughlan, HSE-Health Protection Surveillance Centre, 
Dublin
Joan O’Donnell, HSE-Health Protection Surveillance Centre, 
Dublin
Michael Joyce, Irish College of General Practitioners, Dublin
Claire Collins, Irish College of General Practitioners, Dublin
Linda Dunford, National Virus Reference Laboratory, 
University College Dublin
Joanne Moran, National Virus Reference Laboratory, 
University College Dublin
Grainne Tuite, National Virus Reference Laboratory, 
University College Dublin
Margaret Duffy, National Virus Reference Laboratory, 
University College Dublin
Jeff Connell, National Virus Reference Laboratory, University 
College Dublin
Cillian de Gascun, National Virus Reference Laboratory, 
University College Dublin
Italy
Italian Influenza Surveillance System:
Caterina Rizzo, Istituto Superiore di Sanità, Rome
Antonino Bella, Istituto Superiore di Sanità, Rome
Valeria Alfonsi, Istituto Superiore di Sanità, Rome
Maria Rita Castrucci, National Influenza Center, Istituto 
Superiore di Sanità, Rome
Simona Puzelli, National Influenza Center, Istituto Superiore 
di Sanità, Rome
EU-PC study:
Elisabetta Pagani, Regional Reference Laboratory for influ-
enza, TRENTINO ALTO ADIGE, Bolzano
Valeria Ghisetti, Regional Reference Laboratory for influen-
za, PIEMONTE
Elena Pariani, Regional Reference Laboratory for influenza, 
LOMBARDIA, Milano
Fausto Baldanti, Regional Reference Laboratory for influen-
za, LOMBARDIA, Pavia
Giorgio Palù, Regional Reference Laboratory for influenza, 
VENETO
Pierlanfranco D’Agaro, Regional Reference Laboratory for in-
fluenza, FRIULI VENEZIA GIULIA
Filippo Ansaldi, Regional Reference Laboratory for influenza, 
LIGURIA
Paola Affanni, Regional Reference Laboratory for influenza, 
EMILIA-ROMAGNA
Gian Maria Rossolini, Regional Reference Laboratory for in-
fluenza, TOSCANA
Barbara Camilloni, Regional Reference Laboratory for influ-
enza, UMBRIA
Patrizia Bagnarelli, Regional Reference Laboratory for influ-
enza, MARCHE
Maurizio Sanguinetti, Regional Reference Laboratory for in-
fluenza, LAZIO
Luigi Atripaldi, Regional Reference Laboratory for influenza, 
CAMPANIA
Maria Chironna, Regional Reference Laboratory for influen-
za, PUGLIA
Caterina Serra, Regional Reference Laboratory for influenza, 
SARDEGNA
Francesco Vitale, Regional Reference Laboratory for influ-
enza, SICILIA
EU-H study:
Maria Chironna, Department of Biomedical Science and 
Human Oncology, Bari hospital, Bari
Cinzia Germinario, Department of Biomedical Science and 
Human Oncology, Bari hospital, Bari
Andrea Orsi, San Martino Polyclinic Hospital, University of 
Genoa, Genoa
Filippo Ansaldi, San Martino Polyclinic Hospital, University 
of Genoa, Genoa
Ilaria Manini, Department of Molecular and Developmental 
Medicine, University of Siena, Siena
Emanuele Montomoli, Department of Molecular and 
Developmental Medicine, University of Siena, Siena
Christian Napoli, Sant’Andrea Hospital, Sapienza University 
of Rome, Rome
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Giovanni Battista Orsi, Sant’Andrea Hospital, Sapienza 
University of Rome, Rome
Navarra:
EU-H study:
Itziar Casado, Instituto de Salud Pública de Navarra, IdiSNA, 
CIBERESP, Pamplona
Jesús Castilla, Instituto de Salud Pública de Navarra, IdiSNA, 
CIBERESP, Pamplona
Leticia Fernandino, Instituto de Salud Pública de Navarra, 
IdiSNA, CIBERESP, Pamplona
Iván Martínez-Baz, Instituto de Salud Pública de Navarra, 
IdiSNA, CIBERESP, Pamplona
Guillermo Ezpeleta, Instituto de Salud Pública de Navarra, 
IdiSNA, CIBERESP, Pamplona
Ana Navascués, Complejo Hospitalario de Navarra, IdiSNA, 
Pamplona
Alejandra Pérez-García, Complejo Hospitalario de Navarra, 
IdiSNA, Pamplona
Aitziber Aguinaga, Complejo Hospitalario de Navarra, 
IdiSNA, Pamplona
Carmen Ezpeleta, Complejo Hospitalario de Navarra, IdiSNA, 
Pamplona
The Netherlands
EU-PC and EU-H studies:
Adam Meijer, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
Sharon van den Brink, National Institute for Public Health 
and the Environment (RIVM), Bilthoven
Wim van der Hoek, National Institute for Public Health and 
the Environment (RIVM), Bilthoven
Gabriel Goderski, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
Lisa Wijsman, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
EU-PC study:
Mariam Bagheri, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
Frederika Dijkstra, National Institute for Public Health and 
the Environment (RIVM), Bilthoven
Marit de Lange, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
Ton Marzec, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
Pieter Overduin, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
Anne Teirlinck, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
Erny Wentink, Netherlands Institute for Health Services 
Research (NIVEL), Utrecht
Gé Donker, Netherlands Institute for Health Services 
Research (NIVEL), Utrecht
EU-H study:
Sierk Marbus, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
Rianne van Gageldonk- Lafeber, National Institute for Public 
Health and the Environment (RIVM), Bilthoven
Peter Schneeberger, Jeroen Bosch Hospital, ‘s Hertogenbosch
Jan Jelrik van Oosterheert, University Medical Center Utrecht, 
Utrecht
Valentijn Schweitzer, University Medical Center Utrecht, 
Utrecht
Geert Groeneveld, Leiden University Medical Center, Leiden
Portugal
EU-PC and EU-H studies:
Baltazar Nunes, Departamento de Epidemiologia, Instituto 
Nacional de Saúde Dr. Ricardo Jorge, Lisbon
Ausenda Machado, Departamento de Epidemiologia, 
Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon
Ana Paula Rodrigues, Departamento de Epidemiologia, 
Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon
Verónica Gomez, Departamento de Epidemiologia, Instituto 
Nacional de Saúde Dr. Ricardo Jorge, Lisbon
Irina Kislaya, Departamento de Epidemiologia, Instituto 
Nacional de Saúde Dr. Ricardo Jorge, Lisbon
EU-PC study:
Raquel Guiomar, Departamento de Doenças Infeciosas, 
Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon
Pedro Pechirra, Departamento de Doenças Infeciosas, 
Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon
Paula Cristóvão, Departamento de Doenças Infeciosas, 
Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon
Inês Costa, Departamento de Doenças Infeciosas, Instituto 
Nacional de Saúde Dr. Ricardo Jorge, Lisbon
EU-H study:
António Panarra, Centro Hospitalar de Lisboa Central, Lisbon
Rita Côrte-Real, Centro Hospitalar de Lisboa Central, Lisbon
José Poças, Centro Hospitalar de Setúbal, Setúbal
Maria João Peres, Centro Hospitalar de Setúbal, Setúbal
Spain
The cycEVA work group
Amparo Larrauri:, National Centre of Epidemiology, Institute 
of Health Carlos III, CIBERESP
Alin Gherasim, National Centre of Epidemiology, Institute of 
Health Carlos III, CIBERESP
Francisco Pozo, Inmaculada Casas National Centre for 
Microbiology, National Influenza Reference Laboratory,
HO-National Influenza Centre, Institute of Health Carlos III
Luis García Comas, Dirección General de Salud Pública, 
Comunidad de Madrid
María Esther Insua Marisquerena, Dirección General de 
Salud Pública, Comunidad de Madrid
Juan Carlos Galán, Laboratorio Hospital Ramón y Cajal
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Mª Dolores Folgueira, Laboratorio Hospital Doce de Octubre
Fernando Gonzalez Carril, Departamento de Salud, Gobierno 
del País Vasco,
Rosa Sancho Martínez, Departamento de Salud, Gobierno 
del País Vasco
Gustavo Cilla Laboratorio Hospital Donostia, CIBERER
Jesús Castilla, Navarra Institute for Health Research IdiSNA, 
Pamplona, CIBERESP
Manuel García Cenoz, Navarra Institute for Health Research 
IdiSNA, Pamplona, CIBERESP
Ana Navascués, Complejo Hospitalario de Navarra
Carmen Quiñones Rubio, Dirección General de Salud Pública 
y Consumo de La Rioja
Eva Martinez Ochoa, Dirección General de Salud Pública y 
Consumo de La Rioja
Miriam Blasco, Laboratorio Hospital San Pedro de Logroño
Jaume Gimenez Duran, Servicio de Epidemiología, Dirección 
General de Salud Pública, Mallorca
Juana Maria Vanrell, Servicio de Epidemiología, Dirección 
General de Salud Pública, Mallorca
Jordi Reina, Laboratorio del Hospital Son Espases, Mallorca
Daniel Castrillejo, Servicio de Epidemiología. DGSC, 
Consejería de Bienestar Social y Sanidad, Ciudad Autónoma
e Melilla
The Spanish Influenza Sentinel Surveillance System:
Amparo Larrauri, National Centre of Epidemiology, Institute 
of Health Carlos III, CIBERESP
Alin Manuel Gherasim, National Centre of Epidemiology, 
Institute of Health Carlos III, CIBERESP
Concha Delgado, National Centre of Epidemiology, Institute 
of Health Carlos III, CIBERESP
Jesus Oliva National Centre of Epidemiology, Institute of 
Health Carlos III, CIBERESP Francisco Pozo, National Centre 
for Microbiology, National Influenza Reference Laboratory, 
WHO-National Influenza Centre, Institute of Health Carlos III.
Inmaculada Casas, National Centre for Microbiology, 
National Influenza Reference Laboratory, WHO-National 
Influenza Centre, Institute of Health Carlos III.
The Spanish IMOVE+ study: the hospitals component:
Amparo Larrauri, National Centre of Epidemiology, Institute 
of Health Carlos III, CIBERESP
Alin Manuel Gherasim, National Centre of Epidemiology, 
Institute of Health Carlos III, CIBERESP
Francisco Pozo, National Centre for Microbiology, National 
Influenza Reference Laboratory, WHO-National Influenza 
Centre, Institute of Health Carlos III.
Inmaculada Casas, National Centre for Microbiology, 
National Influenza Reference Laboratory, WHO-National 
Influenza Centre, Institute of Health Carlos III.
Miriam García Dirección General de Salud Pública, Aragón;
Miriam Latorre, Hospital Universitario Miguel Servet, 
Zaragoza
Ana María Milagro Beamonte, Hospital Universitario Miguel 
Servet, Zaragoza
Ana Martinez Sapiña, Hospital Universitario Miguel Servet, 
Zaragoza
Madalen Oribe Amores, Subdirección de Salud Pública 
Gipuzkoa, País Vasco
Amaia Aizpurúa, Laboratorio Hospital Donostia, CIBERER
Gustavo Cilla, Laboratorio Hospital Donostia, CIBERER
Milagrosa Montes, Laboratorio Hospital Donostia, CIBERER
Sweden
EU-PC study:
Katherina Zakikhany, The Public Health Agency of Sweden, 
Stockholm
Mia Brytting, The Public Health Agency of Sweden, Stockholm
Åsa Wiman, The Public Health Agency of Sweden, Stockholm
Annasara Carnahan, The Public Health Agency of Sweden, 
Stockholm
United Kingdom
UK study:
Richard Pebody, Public Health England, London
Fiona Warburton, Public Health England, London
Abdelmajid Djennad, Public Health England, London
Joanna Ellis, Public Health England, London
Nick Andrews, Public Health England, London
Diogo Marques, Health Protection Scotland, Glasgow
Simon Cottrell, Public Health Wales, Cardiff
Arlene Reynolds, Health Protection Scotland, Glasgow
Rory Gunson, West of Scotland Specialist Virology Centre, 
Glasgow
Monica Galiano, Public Health England, London
Angie Lackenby, Public Health England, London
Chris Robertson, University of Strathclyde, Glasgow
Mark O’Doherty, Public Health Agency Northern Ireland, 
Belfast
Mary Sinnathamby, Public Health England, London
Ivelina Yonova, University of Surrey, Guildford, Royal College 
of General Practitioners, London
Catherine Moore, Public Health Wales, Cardiff
Muhammed Sartaj, Public Health Agency Northern Ireland, 
Belfast
Simon de Lusignan, University of Surrey, Guildford, Royal 
College of General Practitioners, London
Jim McMenamin, Health Protection Scotland, Glasgow
Maria Zambon, Public Health England, London
EpiConcept
EU-PC and EU-H studies: Marta Valenciano, Alain Moren, 
EpiConcept, Paris
EU-PC study: Esther Kissling, EpiConcept, Paris
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EU-H study: Marc Rondy, EpiConcept, Paris
European Centre for Disease Prevention and Control (ECDC)
Pasi Penttinen, European Centre for Disease Prevention and 
Control
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